TodayHansoh Pharma announced that the UK Medicines and Healthcare products Regulatory Agency（MHRA) has approved its third-generationEGFRTyrosine Kinase Inhibitor (TKI) Ameitinib (UK trade name:Aumseqa) has been granted marketing authorization as a single-agent therapy for: adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and has activatedEGFRFirst-line treatment for patients with mutations, and adult locally advanced or metastaticEGFR T790MMutation PositiveNSCLCPatient Treatment.

Screenshot source: Hansoh Pharma official website

Public information shows,Almonertinib Mesylate Tablets are third-generation.EGFR-TKIInnovative drug, previously approved in China for four indications, respectively:2020Year3Month, approved for use in patients previously treated withEGFR-TKITreatment Progress, andT790MMutation-positive locally advanced or metastaticNSCLCPatient;2021Year12Month, approved for use withEGFRExon19Missing or Exon21(L858R)Positive for substitution mutations, locally advanced or metastaticNSCLCFirst-line treatment for adult patients;2025Year3Month, approved for use in patients with unresectable locally advanced disease who have not experienced disease progression after platinum-based radical chemoradiotherapy.EGFRExon19Missing or Exon21(L858R)Substitution MutationNSCLCPatient Treatment;2025Year5Month, approved for use inII-IIIBThe period hasEGFRExon19Missing or Exon21(L858R)Adults with substitution mutationsNSCLCThe patient's treatment requires that the patient has previously undergone surgical resection and, as determined by the doctor, may or may not receive adjuvant chemotherapy.

It is reported that,The product has anotherNDAAlready Obtained in ChinaNMPAAcceptance,ForIn combination with pemetrexed and platinum-based chemotherapy drugs, it is suitable forEGFRExon19Missing or Exon21(L858R)Local Advanced or Metastatic Substitution MutationNSCLCFirst-line treatment for adult patients.

Today, WANTAI BioPharm announced，Its nine-valent human papillomavirus vaccine (Escherichia coli) (trade name: Cecolin)9) has been approved for marketing by the NMPA. This is the first domestically produced [product] in China to be marketed.NinePriceHPVVaccine.

 Screenshot source: Announcement on the official website of Beijing WANTAI BioPharm

Previously，Globally, there is only one nine-valent vaccine.HPVVaccine Launch, from MerckTheGardasil®9In2018Approved in China in the year, applicable9~45-Year-Old Female, Among Which9~14Two-dose vaccination schedule can be adopted at the age of0，6~12Month),15~45Three-dose vaccination schedule (0, 2, and 6 months)。

WANTAI BioPharm's Nine-Valent Vaccine Recently ApprovedHPVVaccine CoverageHPV16/18/31/33/45/52/58Seven high-risk types andHPV6/11Two low-risk types can prevent diseases related to the infection of the aforementioned human papillomavirus types.WANTAI BioPharm's newly approved nine-valent HPV vaccine is suitable for females aged 9 to 45. A two-dose vaccination schedule (0, 6 months) can be adopted for those aged 9 to 17, and a three-dose schedule (0, 1, and 6 months) is recommended for those aged 18 to 45.

Today, Johnson & Johnson (Johnson & Johnson) Company AnnouncementItsⅢPeriodAMPLITUDEThe first results of the study. The study evaluatedPARPInhibitorniraparibIn combination with abiraterone acetate and prednisone (AAP) In carrying homologous recombination repair (HRR) Gene Mutation (IncludingBRCA) Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Efficacy in patients.

AMPLITUDEIs an ongoing international multi-center, randomized double-blind, placebo-controlledⅢA study aimed at evaluatingAkeega（niraparibDual-Mechanism Compound Tablet with Abiraterone Acetate[DAT]) Combined with prednisone and androgen deprivation therapy (ADT) efficacy and safety. The control group was matched with placebo./Abiraterone acetate combined with prednisoneADT. The research subject is696Example CarryingHRRGene MutationmCSPCPatient. The primary endpoint of the study was radiological progression-free survival.

The research results showed that the combination regimen achieved progression-free survival (PFS) in imaging.rPFS`) and time to symptom progression (`TSP) achieved clinically significant and statistically significant improvements, and preliminarily demonstrated an improvement in overall survival (OS) The improving trend highlights the potential of this treatment combination in delaying disease progression and symptom deterioration. According to the press release, this ismCSPCAmong the patients,PARPThe First Clinical Improvement Effect of Combination Therapy with InhibitorsⅢPhase Research.

Editors: Fan Xiaoyan, Li Yongshi

Layout Editor: Yu Yuanze

Reviewed by: Ma Fei, Zhang Song

Total $60 Billion! Sanofi, Lilly, AstraZeneca, Johnson & Johnson, Pfizer and Other Giants Drive Over 40 Deals in New M&A Surge?

MSD China Changes Leadership, Novo Nordisk CEO Steps Down — What’s Behind the Shakeup at MNCs?

IPO "Fast Track" Arrives! Who Will Stand Out: PAG Biotech, Biocytogen, Biscien Life, or Bibite?

www.yyjjb.com.cn

Insight into Industry Trends

Long press to followPharmaceutical Economy Herald

《China Prescription Drug》

Academic Official Account

Focus on Pharmaceutical Academics and Evidence-Based Research

Press and hold to followChina Prescription Drug    

"Pharmaceutical Economy Herald"

Terminal Official Account

Record Major Events in the Pharmaceutical Industry Terminal

Long press to follow21st Century Pharmacy